Pyramax® granules

Shin Poong

Product category
  • 3-day cure, artemisinin-based combination therapy (pyronaridine-artesunate)

Therapeutic indication


  • Pyramax granules: for the treatment of uncomplicated malaria infection caused by P. falciparum or P. vivax in children and infants weighing 5kg to under 20kg

  • Once-daily for 3 days

  • 28-day PCR-corrected ACPR* >97%

  • 42-day PCR-corrected ACPR* 90%–95%

Key features
  • Only ACT approved by a stringent regulatory authority for both P. falciparum and P. vivax (blood-stage)
  • No food restrictions
  • Child-friendly granules
  • WHO Information Note of October 2019 now supports use, yet not formally included in WHO Malaria Treatment Guidelines

  • Included in WHO Essential Medicines List (adults and children)
  • Included in national treatment guidelines of Côte d’Ivoire, Niger and Republic of Congo
  • Approved in 16 countries, country launches began in 2018 in sub-Saharan Africa
Next milestone
  • National registrations

  • Completion of multi-country phase IIIb/IV CANTAM study for publication

  • Commercial introduction in Africa

  • Development project team led by University of Iowa

MMV Project Director
  • Adam Aspinall

* ACPR = adequate clinical and parasitological response